What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Carcinoma, Oncology, Surgery and Radiology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Gynecology.
David G. Mutch has researched Carcinoma in several fields, including Cervix, Metastasis, Stage, Radiation therapy and Adenocarcinoma.
His study in Oncology is interdisciplinary in nature, drawing from both Breast cancer and Endometrial cancer.
His studies in Cancer research integrate themes in fields like Molecular biology, Uterine serous carcinoma and microRNA, Gene.
His Serous fluid study incorporates themes from Serous carcinoma, DNA methylation and Carcinosarcoma.
His most cited work include:
- Integrated genomic analyses of ovarian carcinoma (4769 citations)
- Integrated genomic characterization of endometrial carcinoma (2370 citations)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Endometrial cancer, Cancer and Surgery.
His Internal medicine study frequently links to related topics such as Gynecology.
The concepts of his Oncology study are interwoven with issues in Serous fluid, Carcinoma, Disease, Stage and Radiation therapy.
His research in Endometrial cancer intersects with topics in MLH1, Cancer research, Cohort, Microsatellite instability and Adjuvant therapy.
The study incorporates disciplines such as Tumor necrosis factor alpha, Immunology, Cell culture, DNA methylation and Carcinogenesis in addition to Cancer research.
Much of his study explores Surgery relationship to Gastroenterology.
He most often published in these fields:
- Internal medicine (43.21%)
- Oncology (34.42%)
- Endometrial cancer (22.94%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (43.21%)
- Oncology (34.42%)
- Endometrial cancer (22.94%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Endometrial cancer, Cancer and Gynecologic oncology.
His work on Ovarian cancer, Disease, Chemotherapy and Proportional hazards model as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science.
His Ovarian cancer study integrates concerns from other disciplines, such as Cancer research and Stromal cell.
His studies deal with areas such as Uterine cancer, Metastasis, Receptor tyrosine kinase and Serous fluid as well as Cancer research.
His studies examine the connections between Oncology and genetics, as well as such issues in Stage, with regards to Radiology.
His Gynecologic oncology research incorporates elements of Retrospective cohort study, Family medicine and Hazard ratio.
Between 2015 and 2021, his most popular works were:
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
- Pan-cancer analysis of whole genomes (538 citations)
- Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology (245 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Oncology, Endometrial cancer, Cancer and Gynecologic oncology.
His study in Proportional hazards model, Confidence interval, Survival rate, Serous fluid and Hazard ratio falls within the category of Internal medicine.
His Oncology research incorporates themes from Chemotherapy, Cervical cancer, Carcinoma, Disease and Ovarian cancer.
His research integrates issues of Clinical trial, Cohort, Pathology, Carcinosarcoma and Adjuvant therapy in his study of Endometrial cancer.
His Cancer study combines topics from a wide range of disciplines, such as Cancer research, Gynecology, Incidence and Obstetrics and gynaecology.
His biological study spans a wide range of topics, including In vitro, DNA methylation, Mutation, Uterine cancer and Molecular biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
